Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

• Published in: Diagnostic microbiology and infectious disease 2011-05, Vol.70 (1), p.150-153
• Main Authors: Lee, Nan-Yao, Huang, Wei-Han, Tsui, Ko-Chung, Hsueh, Po-Ren, Ko, Wen-Chien
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Anti-Bacterial Agents - administration & dosage; Bacteremia; Bacteremia - drug therapy; Bacteremia - microbiology; Bacterial diseases; Bacterial sepsis; Bacteriology; beta-Lactamases - biosynthesis; beta-Lactams - administration & dosage; Biological and medical sciences; Carbapenem; Carbapenems - administration & dosage; ESBL; Escherichia coli; Escherichia coli - enzymology; Escherichia coli - isolation & purification; Escherichia coli Infections - drug therapy; Escherichia coli Infections - microbiology; Female; Fundamental and applied biological sciences. Psychology; Human bacterial diseases; Humans; Imipenem - administration & dosage; Infectious Disease; Infectious diseases; Internal Medicine; Klebsiella Infections - drug therapy; Klebsiella Infections - microbiology; Klebsiella pneumoniae; Klebsiella pneumoniae - enzymology; Klebsiella pneumoniae - isolation & purification; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; Thienamycins - administration & dosage; Treatment Outcome
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2010.12.008

Abstract For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)–producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.